GlassScriptPhysician profile
Steven J Ugent
NPI 1417050436
$137,738.86
in general payments reported to CMS, 2019-2025
28 companies · $8,512 in 2025
The $8,512 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $16K · 2021: $7,089 · 2022: $17K · 2023: $12K · 2024: $10K · 2025: $8,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $5,383 · Travel and Lodging: $119 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,250.00 |
| Food and Beverage | $5,382.53 |
| Travel and Lodging | $119.32 |
| Education | $107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $83,029.45 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $21,835.64 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $13,892.10 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Celgene Corporation | $8,868.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $4,061.77 | 2019-2025 | |
| Janssen Biotech, INC. | $1,665.31 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $1,164.89 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $715.39 | 2022-2025 | Sotyktu |
| Ucb, INC. | $620.44 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $324.86 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $310.02 | 2019-2025 | |
| Pfizer INC. | $287.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $209.21 | 2021-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $180.90 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $155.42 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $71.83 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $64.20 | 2019-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $51.88 | 2019 | |
| Janssen Scientific Affairs, LLC | $29.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.17 | 2022 | |
| Dermira, INC. | $27.67 | 2019 | |
| Allergan, INC. | $27.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.84 | 2020 | |
| Almirall LLC | $21.22 | 2019 | |
| Genentech USA, INC. | $19.00 | 2019 | |
| Incyte Corporation | $18.78 | 2021 | |
| Organon LLC | $18.64 | 2025 | Vtama |
| Sanofi Pasteur INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ugent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.